patients, combinations of select clinical criteria for the diagnosis of VAP may lead to overdiagnosis. Additionally, intensivists generally have a low threshold for initiating treatment with anti-infectives in cases of suspected VAP (5) . In practice, these two factors combine to reinforce each other and result in broader and more extensive use of antibiotics in the ICU. This phenomenon, in part, accounts for the growing antimicrobial resistance noted in the ICU (6) .
Invasive lower airway sampling, usually with either bronchoalveolar lavage (BAL) or protected specimen brush, represents an alternative to clinical criteria for the identification of VAP. Invasive testing is attractive since it intuitively appears more objective than clinical criteria. Invasive sampling further allows the physician to identify the specific culprit pathogen and to direct therapy toward this organism. As a result, antibiotics can be better tailored to treat the infection. Some investigators have hypothesized that an invasive diagnostic approach to VAP can serve as an important tool to promote more appropriate antibiotic utilization and to help limit the development of resistance (1, 2) .
Prior studies to define the value of differing diagnostic approaches to VAP have been confounded by the absence of an accepted "gold standard." Although the use of autopsy findings for the histologic confirmation of alveolar infection is appealing and has been studied, employing autopsy as a reference standard injects bias into calculations regarding specificity and sensitivity (7) . Patients surviving VAP are likely to be systematically different from those who die of the disease. Therefore, the most appropriate way to determine the role for invasive sampling in the diagnosis of VAP is to measure if and how this technology alters important outcomes such as survival. Over the last decade, several studies have examined the effect of invasive testing on mortality in critically ill patients suspected of having VAP. These trials, however, have produced conflicting results. Additionally, as noted previously, the potential value of invasive sampling may lie in its ability to either help ensure that the clinician prescribes appropriate antibiotic coverage or allow the physician to narrow or discontinue antibiotics when they may not be required.
To better assess the impact of invasive cultures on outcomes in VAP, we conducted a meta-analysis of clinical trials investigating this topic. We hypothesized that invasive testing would consistently lead to changes in antibiotic utilization but that this adjustment in management would not affect all-cause mortality. We additionally attempted to locate potentially relevant trials by reviewing the references of the selected articles and by contacting experts in the field. We had no language restrictions and did not restrict our search to articles dealing only with standard bronchoscopy. We sought reports describing use of mini-BAL as well. All analyses had to describe mortality in VAP as a function of the diagnostic tool employed.
METHODS
Two investigators examined potentially relevant articles and abstracts independently to ensure that they met our inclusion criteria. Studies exploring patients who underwent invasive testing for the diagnosis of severe community-acquired pneumonia requiring mechanical ventilation were excluded. We also excluded investigations that did not report mortality as an end point or that failed to describe the impact of invasive testing on antibiotic prescribing. Protocols could use any method of invasive testing (e.g., BAL, mini-BAL, etc.). We initially intended to focus only on randomized intervention trials. However, because of the paucity of available studies fulfilling our inclusion criteria (discussed later), we subsequently evaluated prospective observational trials that reported the effect of invasive testing on anti-infective management.
Study Evaluation and Data Extraction. Two investigators independently rated the quality of the randomized trials included in this review using the scoring system created by Jadad et al. (8) No similar quality evaluation was performed for the observational reports. Two investigators also independently extracted the relevant data in duplicate. Specifically, we collected information dealing with the methods used for the diagnosis of VAP, the severity of illness of the patients studied, and the organisms implicated as the causative pathogens. Duration of mechanical ventilation before the onset of VAP and the rate at which invasive testing confirmed the diagnosis of VAP were further recorded. Mortality served as the primary end point.
To explore antibiotic management, our secondary end point, we determined how often invasive testing resulted in a change in the antibiotics given to the patient. We defined a change as either the addition or discontinuation of any anti-infective. Ensuring that the patient receives an antibiotic that possesses activity against the responsible pathogen is an important predictor of survival in VAP. Therefore, to account for this potential confounder, we abstracted information regarding the frequency that subjects were initially treated with an inadequate antibiotic regimen (e.g., one either that did not cover the pathogen or to which the pathogen was resistant). No manuscript consistently reported the timing of antibiotic delivery relative to the performance of invasive testing.
Statistical Analysis. To assess for the potential of publication bias that might affect our conclusions, we visually inspected funnel plots and computed the Begg's statistic. Agreement between the two investigators in their quality ratings of the clinical trials was compared with the kappa statistic. To summarize the effect of invasive testing on mortality, we relied on the risk differences as computed based on the odds ratios from each of the randomized trials and their respective 95% confidence intervals (CIs). Heterogeneity was assessed visually with Galbraith plots as well as with Q statistics (chi-square) using the methods of Mantel and Haenszel. We employed a random-effects model and calculated a summary odds ratio to describe the relationship between invasive testing and mortality. Because of design limitations inherent in observational, nonrandomized studies, we elected a priori not to pool mortality rates from these types of reports with the observations from the randomized protocols.
For antibiotic management alterations, we conducted three separate analyses. First, for the randomized trials, we used a random effects model to calculate a summary odds ratio to evaluate if invasive testing resulted in adjustments to antibiotic treatment. Second, because of the lack of a control arm in the majority of the observational studies, data from these investigations were analyzed separately from the randomized trials. To accomplish this, results were assessed for heterogeneity and then combined using a random effects approach with weighting calculated using an inverse variance method. Finally, we similarly pooled the findings from all identified reports (both randomized and observational) with respect to antibiotic management.
RESULTS
Our literature search identified 678 potential articles, four of which fulfilled our selection criteria (9 -12) . No studies beyond those located through electronic database searches were found via our hand-searching of abstracts or by con-tacting experts in the field. The four randomized trials included a total of 628 patients. Five additional prospective observational studies reporting the effect of invasive diagnostic strategies on antibiotic management in suspected VAP were also reviewed (13) (14) (15) (16) (17) . The median Jadad quality score of the randomized studies was 5, and there was good interrater agreement in the quality scoring (kappa ϭ 1.00, p Ͻ .0001). Based on visual inspection of the funnel plot (not shown) and the Begg's statistic (0.09), there was no evident publication bias. Table 1 summarizes the characteristics of the randomized trials. Investigators employed a variety of methods for the diagnosis of VAP, with two protocols using protected specimen brush combined with BAL.
None of the trials were blinded, and only one was multiple-centered. Patients in the intervention and standard approach arms appeared well matched with respect to severity of illness. The mean Acute Physiology and Chronic Health Evaluation II scores varied from 15 to 20 in the three investigations recording this measure. The mean duration of mechanical ventilation before evaluation for VAP was Ͼ6 days in all of the randomized trials. There was heterogeneity in the incidence of positive culture results among the subjects undergoing invasive testing, which ranged from 44% in the report by Fagon et al. (11) to 69% in the study conducted by Sole Violan and colleagues (12) . The most frequently isolated pathogens were Pseudomonas aeruginosa (18%) and Staphylococcus aureus (16%). Methodologically, Fagon et al. and Sole Violan et al. relied on qualitative endotracheal aspirates for the control arm, whereas quantitative endotracheal aspirates were used in the other two trials.
Importantly, antibiotic management (Table 2 ) differed across each of the trials. For individuals in the invasive sampling cohorts, antibiotics were given or modified based on the results of Gram stains from specimens obtained at time of bronchoscopy in two investigations. In the other trials, antibiotic prescribing was either left to the attending physician or guided based on a local protocol. For patients in the noninvasive groups, antibiotic therapy was directed by either physician preference or the American Thoracic Society position statement on In the invasive arm there were 11.5 Ϯ 9.0 antibiotic-free days vs. 7.5 Ϯ 7.6 in the standard arm. Antibiotic-free days measure the number of days during the 28 days after study enrollment that the patient is both alive and not receiving an antibiotic. nosocomial pneumonia (18) 
Mortality in the invasive diagnostic arms ranged from 22% to 46% compared with 21% to 46% in the subjects randomized to noninvasive diagnostic strategies. Fagon et al. (11) -1.41 ). An analysis of rates of inappropriate antibiotic prescribing, however, reveals significant differences between the studies. As Figure 2 demonstrates, for three studies, those by Sanchez-Nieto et al. (9), Ruiz et al. (10) , and Sole Violan et al. (12) , there was no difference between the invasive and noninvasive cohorts with respect to the frequency of inappropriate antibiotic prescribing. Individuals not undergoing invasive testing in the study by Fagon and coworkers (11) were statistically more likely to be treated with an antibiotic that did not provide coverage for the culprit organism (p Ͻ .0001) (11) . To address the impact of differences in appropriate antibiotic therapy on outcomes, we conducted a separate sensitivity analysis excluding the report by Fagon et al. from the meta-analysis. Among the three remaining studies, invasive testing continued not to affect mortality (OR 1.14, 95% CI 0.58 -2.23).
With respect to antibiotic management, in all reports bronchoscopy was often associated with alterations in antibiotic management. Among the three randomized trials discussing the relationship between diagnostic approach and subsequent changes in antibiotic management (Fig. 3) , patients undergoing bronchoscopy were nearly three times more likely to have their antibiotic prescription adjusted (odds ratio 2.85, 95% CI 1.45-5.59) (9, 10, 12) . To explore if the use of inappropriate antibiotics accounted for this observation, we pooled the rate of this across these three studies. Among all the patients undergoing bronchoscopy in these three trials, 20.8% received inadequate antibiotics compared with 12.8% of persons managed without invasive testing. This discordance, however, was not statistically significant (odds ratio 1. ports did not consistently describe the precise reasons for changes in antibiotic use (e.g., discontinuation of some agents, addition of others).
The five prospective observational studies examining invasive testing comprised 635 subjects (13) (14) (15) (16) (17) . The report by Heyland et al. (16) was unique among the observational trials because it contained a control arm. Patients in this analysis were drawn from a prospective, randomized trial exploring options for stress ulcer prophylaxis in mechanical ventilation (19) . As with the randomized investigations, several different techniques were used for invasive lower airway sampling (Table 3) . Nonetheless, P. aeruginosa and S. aureus were the predominant pathogens. Subjects in the observational studies appeared to be more severely ill than those in the randomized trials (Table 3) , and the observed mortality reflected this (range 24 -67%). The rate of initially inappropriate antibiotic administration in persons with VAP confirmed by invasive testing also varied widely from a low of 8% to a high of 73% (Table 4) .
In all of the observational studies, antibiotic prescribing was at the discretion of the clinician. These studies, however, demonstrate (Fig. 4) that invasive sampling leads to modifications in the antibiotic regimen in more than half of patients (Q statistic 58.4, test for heterogeneity p Ͻ .001, pooled estimate 50.3%, 95% CI 35.9 -64.6%). These composite changes in antibiotic use did not solely reflect the discontinuation of treatment in patients determined not to have VAP. Restricting the analysis to patients with bronchoscopically confirmed VAP underscores that invasive testing often alters antibiotic management in these subjects as well. Specifically, physicians modified their antibiotic choices in 52.3% of patients with confirmed VAP (Q statistic 187.4, test for heterogeneity p Ͻ .001, pooled estimate 95% CI 27.3-77.3%). Combining both the randomized and observational studies does not appreciably alter this observation (Q statistic 107.6, test for heterogeneity p Ͻ .001, pooled estimate 43.9%, 95% CI 34.4 -54.4%).
DISCUSSION
Few trials have systematically examined the impact of diagnostic techniques on outcomes for patients suspected of suffering from VAP. Nonetheless, this meta-analysis reveals that invasive strategies for the diagnosis of VAP do not alter mortality. Bronchoscopy and other nonbronchoscopic invasive approaches to VAP, though, have a major impact on antibiotic utilization as invasive cultures result in alterations in antibiotic prescribing. Observational trials exploring the effect of lower airway sampling on antibiotic prescribing support this finding.
If bronchoscopy affects antibiotic management, why does it not improve survival? The most likely explanation for this discordance is that prompt, adequate initial antimicrobial coverage is the crucial issue affecting survival. Specifically, inappropriate or inadequate treatment refers to the use of antibiotics with either limited or no in vitro activity against the microorganism causing the infection (20) . Among critically ill patients, several recent reports have documented that initially inadequate antibiotic coverage is an independent predictor of mortality. For example, in analyzing a clinical trial of lenercept for septic shock, Harbarth and coworkers (21) noted that inappropriate antimicrobial treatment nearly doubled the risk for death. Similarly, Dhainaut et al. (22) demonstrated that inadequate anti-infective treatment independently heightened the chance for death among subjects with severe sepsis or septic shock, irrespective of whether they received drotrecogin alfa (activated). The importance of appropriate initial antibiotic therapy extends beyond sepsis. In VAP, the focus on the present metaanalysis, Iregui and colleagues (23) observed that initially inappropriate or delayed antibiotic treatment was a strong predictor of death. Since invasive sampling for suspected VAP does not directly affect the initial antibiotic prescription, it is not surprising that it does not alter mortality. Because of the nature of the technology, the culture results from bronchoscopy become available only after the crucial period when the clinician can intervene to maximal effect (24) .
Despite this limitation with invasive diagnostic strategies, our analysis suggests that data obtained from bronchoscopy can play an important role in the management of VAP. First, the antibiotic regimen can be modified once culture results are obtained. In certain cases, the adjustments made to the original antibiotic prescription in the trials we reviewed represented attempts to extend coverage so as to treat a culprit pathogen that was initially missed. Although modifying an initially inappropriate regimen does not guarantee a favorable response, continuing treatment for a documented pneumonia with anti-infectives that are known to be inadequate only undermines efforts to care for the patient (24) . Moreover, subjects failing to respond to therapy are likely to be receiving an inadequate antibiotic regimen (25) . Thus, in these instances, bronchoscopic cultures represent an important way to identify a pathogen not covered by the antibiotic regimen being administered. Second, results from bronchoscopy may be used to narrow antibiotic coverage. Overuse of broad-spectrum antibiotics necessarily creates selection pressure in the ICU and contributes to increasing rates of antimicrobial resistance (6) . With the results from cultures, physicians can potentially narrow both the number and the spectrum of agents employed for the treatment of VAP. As Fagon et al. (11) revealed, reliance on invasive cultures doubled the number of antibiotic-free days by allowing the safe discontinuation of agents not required for the treatment of the patient. Additionally, Sole Violan et al. (12) noted that patients undergoing BAL were nearly three times more likely to have their antibiotic prescription narrowed because of the results of the invasive microbiological testing. In short, bronchoscopy can serve as a tool for antibiotic control and contribute to efforts to minimize the emergence of resistance by promoting de-escalation in antibiotic use. Our hypothesis, however, requires formal testing in a prospective fashion coupled with a careful economic evaluation of the potential implications of this approach.
Based on this meta-analysis, we therefore recommend that physicians adopt procedures and protocols that help to ensure that patients with VAP receive initially appropriate antibiotic therapy. Because of the prevalence of pathogens such as P. aeruginosa and methicillin-resistant S. aureus, accomplishing this will often require the use of broad-spectrum agents at the outset. Bronchoscopy does not represent a tool for increasing rates of initially appropriate antibiotic therapy. Use of bronchoscopy, however, represents one option for attempting to balance the often-competing pressures to initiate therapy with multiple broad-spectrum antibiotics against the imperative to prohibit antibiotic overuse and abuse. Clinicians can employ bronchoscopy to narrow the spectrum of antibiotics given and the duration of total antibiotic exposure. Specifically, invasive cultures provide a method for narrowing therapy when one identifies a single pathogen susceptible to the original antibiotic prescription. Other alternatives for containing antibiotic overuse in the ICU include risk stratification strategies employing the clinical pulmonary infection score (26, 27) . Future trials should explore bronchoscopy in comparison with and in addition to these stratification schemata. Formal economic analysis is also required since prevention of resistance and better antibiotic control may result in cost savings. However, it is important to note that only one trial described the relationship between diagnostic strategy and resource utilization. Specifically, Fagon et al. (11) found that neither ICU length of stay nor duration of mechanical ventilation was altered through use of bronchoscopy.
This multifaceted approach has been validated in other trials. Ibrahim and colleagues (28), for example, created a clinical guideline for the treatment of VAP. As part of their guideline, patients with VAP received a three-drug antibiotic regimen. Invasive cultures when obtained were used to narrow coverage, and antibiotic treatment was limited to 7 days if the patient was responding clinically. With this approach, Ibrahim et al. (28) noted a significant increase in the rate of initially appropriate antibiotic therapy and a decrease in episodes of superinfection. In a large multiple-center trial, Chastre and coworkers (29) randomized patients to receive either 8 or 15 days of antibiotics for bronchoscopically confirmed VAP. As part of their study design, all patients at enrollment underwent invasive testing and were begun on antibiotics concurrently. Bronchoscopy was used to identify individuals treated with an inadequate antibiotic regimen and to narrow the spectrum of coverage. Those consequently found to have received inadequate therapy were excluded from continuation in their trial of short-course therapy (29) . With that caveat, they were able to successfully limit antibiotic use and augmented the number of antibiotic free days by 50% (29) .
Our analysis has several important limitations. First, there were few trials to review and none were blinded. However, to address this, we analyzed results from observational studies to corroborate our conclusions. Second, all of the trials for the meta-analysis were conducted in academic teaching centers, and so it is unclear if these results are generalizable to other institutions. Given differences in microbiology resources in various hospitals, this issue is particularly noteworthy. Third, even though we were able to pool results across four trials, the combined sample size may still have been inadequate for detecting important clinical differences. Fourth, antibiotic prescribing was not necessarily protocolized in all of these investigations. Therefore, this may have introduced significant confounding. Fifth, the trials used different approaches for the control arms. Two investigations-Fagon et al. (11) and Sole Violan et al. (12) -employed qualitative endotracheal aspirates whereas the others relied on quantitative tracheal aspirates. This may have resulted in confounding when we pooled the results among the trials. Similarly, some investigators proscribed that antibiotic therapy continue despite negative cultures, whereas others allowed for the discontinuation of antibiotics. This too confounds our results, and changes in antibiotics management may simply reflect the initial investigational protocols as they were designed. Finally, there was both qualitative and quantitative heterogeneity in the trials, making direct pooling of the data difficult. The use of Gram-stains, which can provide important information to the physician, varied across each of the investigations. In the trial by Fagon et al., for instance, clinicians reviewed Gramstains from all patients, whereas in the report by Ruiz et al. (10) , findings from Gram-stains were only available from the invasive arm. Such variability likely contributed to the way in which antibiotics were either prescribed initially or subsequently modified. To address these and other sources of confounding, we used a conservative randomeffects statistical model.
CONCLUSIONS
Invasive lower airway sampling consistently results in changes to antibiotic management among patients with suspected VAP. Despite these changes, however, regular use of bronchoscopy for the diagnosis of VAP does not alter mortality since it does not directly affect the initial antibiotic prescription. 
